CHF117.38
0.89%
SIX Swiss Exchange, Oct 05, 09:45 am CEST. Market open.
ISIN
CH0012005267
Symbol
NOVN

Novartis Target price 2026 - Analyst rating & recommendation

Novartis Classifications & Recommendation

Buy
47%
Hold
41%
Sell
12%

Novartis Price Target

Target Price CHF130.97
Price CHF116.34
Potential 12.57%
Number of Estimates 27
27 Analysts have issued a price target Novartis 2027 . The average Novartis target price is CHF130.97. This is 12.57% higher than the current stock price. The highest price target is CHF157.50 35.38% , the lowest is CHF99.99 14.05% .
A rating was issued by 34 analysts: 16 Analysts recommend Novartis to buy, 14 to hold and 4 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2027 of 12.57% . Most analysts recommend the Novartis stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion CHF 46.67 48.22
8.91% 3.32%
EBITDA Margin 33.67% 41.16%
5.37% 22.23%
Net Margin 24.83% 29.14%
7.53% 17.38%

29 Analysts have issued a sales forecast Novartis 2026 . The average Novartis sales estimate is

CHF48.2b
unlock
. This is
2.69% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF51.2b 8.99%
unlock
, the lowest is
CHF45.2b 3.65%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 CHF46.7b 8.91%
2026
CHF48.2b 3.32%
unlock
2027
CHF51.2b 6.18%
unlock
2028
CHF54.7b 6.79%
unlock
2029
CHF59.0b 7.95%
unlock
2030
CHF61.9b 4.82%
unlock
2031
CHF61.8b 0.05%
unlock
2032
CHF59.0b 4.60%
unlock
2033
CHF58.4b 1.03%
unlock

24 Analysts have issued an Novartis EBITDA forecast 2026. The average Novartis EBITDA estimate is

CHF19.9b
unlock
. This is
30.71% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF23.6b 55.70%
unlock
, the lowest is
CHF18.0b 18.24%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 CHF15.7b 14.76%
2026
CHF19.9b 26.31%
unlock
2027
CHF21.6b 9.02%
unlock
2028
CHF23.4b 8.02%
unlock
2029
CHF24.9b 6.70%
unlock
2030
CHF26.6b 6.50%
unlock
2031
CHF23.9b 9.99%
unlock
2032
CHF22.8b 4.46%
unlock
2033
CHF22.1b 3.19%
unlock

EBITDA Margin

2025 33.67% 5.37%
2026
41.16% 22.23%
unlock
2027
42.27% 2.70%
unlock
2028
42.75% 1.14%
unlock
2029
42.26% 1.15%
unlock
2030
42.93% 1.59%
unlock
2031
38.67% 9.92%
unlock
2032
38.72% 0.13%
unlock
2033
37.87% 2.20%
unlock

30 Novartis Analysts have issued a net profit forecast 2026. The average Novartis net profit estimate is

CHF14.1b
unlock
. This is
32.96% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF14.9b 41.43%
unlock
, the lowest is
CHF11.5b 8.75%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 CHF11.6b 17.11%
2026
CHF14.1b 21.29%
unlock
2027
CHF15.7b 11.50%
unlock
2028
CHF17.2b 9.83%
unlock
2029
CHF19.0b 10.53%
unlock
2030
CHF20.9b 10.07%
unlock
2031
CHF21.7b 3.84%
unlock
2032
CHF20.9b 3.99%
unlock
2033
CHF21.1b 1.17%
unlock

Net Margin

2025 24.83% 7.53%
2026
29.14% 17.38%
unlock
2027
30.60% 5.01%
unlock
2028
31.47% 2.84%
unlock
2029
32.23% 2.41%
unlock
2030
33.84% 5.00%
unlock
2031
35.16% 3.90%
unlock
2032
35.38% 0.63%
unlock
2033
36.17% 2.23%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share CHF 5.92 7.39
21.81% 24.83%
P/E 15.74
EV/Sales 5.19

30 Analysts have issued a Novartis forecast for earnings per share. The average Novartis EPS is

CHF7.39
unlock
. This is
33.88% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
CHF7.86 42.39%
unlock
, the lowest is
CHF6.05 9.60%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 CHF5.92 21.81%
2026
CHF7.39 24.83%
unlock
2027
CHF8.24 11.50%
unlock
2028
CHF9.05 9.83%
unlock
2029
CHF10.01 10.61%
unlock
2030
CHF11.02 10.09%
unlock
2031
CHF11.44 3.81%
unlock
2032
CHF10.98 4.02%
unlock
2033
CHF11.11 1.18%
unlock

P/E ratio

Current 21.08 18.87%
2026
15.74 25.32%
unlock
2027
14.11 10.36%
unlock
2028
12.85 8.93%
unlock
2029
11.62 9.57%
unlock
2030
10.56 9.12%
unlock
2031
10.17 3.69%
unlock
2032
10.59 4.13%
unlock
2033
10.47 1.13%
unlock

Based on analysts' sales estimates for 2026, the Novartis stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.33 12.68%
2026
5.19 2.61%
unlock
2027
4.89 5.82%
unlock
2028
4.58 6.36%
unlock
2029
4.24 7.37%
unlock
2030
4.05 4.60%
unlock
2031
4.05 0.05%
unlock
2032
4.24 4.82%
unlock
2033
4.29 1.04%
unlock

P/S ratio

Current 4.60 7.97%
2026
4.48 2.62%
unlock
2027
4.22 5.82%
unlock
2028
3.95 6.36%
unlock
2029
3.66 7.37%
unlock
2030
3.49 4.60%
unlock
2031
3.49 0.05%
unlock
2032
3.66 4.82%
unlock
2033
3.70 1.04%
unlock

Current Novartis Upgrades & Downgrades

Analyst Rating Action Date
LANDESBANK BADEN-WUERTTEMBERG
Hold
➜
Hold
Unchanged Sep 23 2026
ROTHSCHILD & CO REDBURN
Sell
➜
Sell
Unchanged Sep 23 2026
BERENBERG
Hold
➜
Hold
Unchanged Sep 21 2026
JEFFERIES
Hold
➜
Hold
Unchanged Sep 18 2026
BAADER EUROPE / ALPHAVALUE
Buy
➜
Buy
Unchanged Sep 17 2026
GUGGENHEIM SECURITIES LLC
Neutral
➜
Neutral
Unchanged Sep 09 2026
TD COWEN
Hold
➜
Hold
Unchanged Sep 08 2026
Analyst Rating Date
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Hold
➜
Hold
Sep 23 2026
Unchanged
ROTHSCHILD & CO REDBURN:
Sell
➜
Sell
Sep 23 2026
Unchanged
BERENBERG:
Hold
➜
Hold
Sep 21 2026
Unchanged
JEFFERIES:
Hold
➜
Hold
Sep 18 2026
Unchanged
BAADER EUROPE / ALPHAVALUE:
Buy
➜
Buy
Sep 17 2026
Unchanged
GUGGENHEIM SECURITIES LLC:
Neutral
➜
Neutral
Sep 09 2026
Unchanged
TD COWEN:
Hold
➜
Hold
Sep 08 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today